Caplin Point Laboratories has informed that it has enclosed a Press Release regarding grant of United States Food and Drug Administration (USFDA) approval for the Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP to its Subsidiary Caplin Steriles.
The above information is a part of company’s filings submitted to BSE.